Abstract:
The present investigation was undertaken to fulfill two aims. First, to investigate the
menopausal experience of women residing in Uttarakhand state which has evaded attention so
far and second to explore a new medicinal herb for preventing postmenopausal bone loss for
which available therapies are limited by several side effects generated.
Interview based cross-sectional survey to reveal age at menopause, frequency and
severity of symptoms and associated factors was conducted among healthy women (n= 129,
35-60 years) in Haridwar district of Uttarakhand. The study included only premenopause, early
postmenopause and late postmenopause women. The recalled mean age was 45.02 ± 4.35 years
and age computed by probit analysis was 46.82 years. Socio-demographic factors like socio
economic status and lifestyles significantly affect the onset of menopause. The Greene
Climacteric Scale was used to assess the frequency and severity of the menopausal symptoms.
Muscle and joint pain was the most prevalent and severe symptom in the whole population as
well in the sample of postmenopausal women. This study is the first of its kind from the
aforementioned state and an effort to fill the abandoned gap.
In an independent project, both acute and chronic treatment studies were conducted to
investigate the potential of Tinospora cordifolia (TC), an herbal medicine to prevent bone loss
in ovariectomized rat model. For the study done acutely, female Sprague Dawley rats (n=7)
were either sham operated (sham ovx) or ovariectomized (ovx) and treated with vehicle (benzyl
benzoate: castor oil; 1:4), E2 (lug/day) or TC stem extract (10, 50, 100 mg/kg b.wt.)
subcutaneouslyfor 4 weeks. At necropsy, Bone Mineral Density (BMD) measured by pQCT in
the metaphysis of tibia was lower in ovx than ovx+E2 or sham ovx group. TC administration to
ovx rats at the dose level 10 mg/kg b.wt. provided bone sparing effects by improving BMD.
This could be explained by a trend towards decreased bone resorption since a significant
positive shift was observed in the serum markers for bone turnover. Administration of TC also
induced normalization of the increased levels of lipoproteins. Uterus and mammary gland
showed no signs of proliferation after acute treatment with TC extract.
Chronic studies were performed with TC (10 mg/kg b.wt.) and E2 (1 ug/d/animal) for
over 3 months. Sham ovx or ovx rats were subcutaneously treated with respective test
substances. Administration of TC extract and E2 for 12 weeks prevented the ovariectomy
induced bone loss in rats. Histology and scanning electron microscopy studies on decalcified
bone samples revealed that TC prevented estrogen deficiency induced decrease in trabecular
thickness and restored the increase in trabecular separation. Efficacy of TC extract was further
ascertained by analyzing the changes occurring in the stability of bone matrix using thermal
analysis. Representative curves so obtained from thermogravimetry, differential thermal
analysis and differential thermo gravimetry record weight changes and associated endothenuic
and exothermic heat effects in bone as a function of temperature (50 to 1500°C). Results
showed greater bone mass loss; particularly in the organic phase of matrix in ovx controls
(69.4%) compared to TC treated animals (56.13%). Additionally, TC extract improved the
energy absorption pattern of tibiae which in turn improve the integrity, structure and hence
compactness of bone.
In search for active phytochemicals that may be responsible for the antiosteoporotic
action of TC, 20- fj hydroxyecdysone (Ecd) was identified as the possible candidate. To test the
bone sparing effect of Ecd, ovx rats were orally treated over 3 months with 18 mg, 57 mg and
121 mg Ecd/day/animal. E2 served as the positive control. BMD of the metaphysis of tibia was
determined before and after the treatment. Results revealed that BMD was reduced by more
than 50% in the control but not in E2 animals. In the Ecd animals, BMD was dose dependently
higher than in the control. Ovariectomy induced elevation in serum bone turnover markers was
also modulated by E2 and Ecd. While cross-laps were lowered in Ecd and E2, osteocalcin was
normalized only by E2. Ecd administration also lack uterotrophic effects. The findings derived
u
from bone mineral density and biochemical parameters indicate that the antiosteoporotic effect
may be attributed at least in part to the presence of Ecd in the extract.
TC has been extensively used as an anti-inflammatory, immunomodulatory, antiarthritic
and anti-diabetic agent in the ayurvedic preparations. Present study is the first attempt
to evaluate its anti-osteoporotic potential. Findings assessed show that TC can prevent
ovariectomy induced bone loss without influences on reproductive organs. If these findings can
be approved in human they may provide a useful alternative to HRT for the treatment of
postmenopausal osteoporosis.